Clinical manifestations in each JSLE subgroup at diagnosis
| Subgroup 1 n=31 (35.6%) | Subgroup 2 n=56 (64.4%) | P value | HR | OR (95% CI) | |
| Age | 10.98±2.79 | 11.91±3.72 | 0.228 | 1.085 | 0.950~1.239 |
| Gender (female, %) | 28 (90.3) | 50 (89.3) | 0.879 | 1.120 | 0.260~4.828 |
| SLEDAI | 15.85±4.51 | 12.81±6.29 | 0.035 | 1.102 | 1.007~1.207 |
| Mucocutaneous diseases | 23 (74.2%) | 43 (76.8%) | 0.787 | 1.515 | 0.417~3.177 |
| Lupus nephritis | 17 (54.8%) | 16 (28.6%) | 0.017 | 3.036 | 1.216~7.576 |
| Neuropsychiatric lupus | 15 (48.4%) | 7 (12.5%) | 0.001 | 6.562 | 2.274~18.940 |
| Serositis | 8 (25.8%) | 11 (19.6%) | 0.506 | 1.423 | 0.563~4.026 |
| Arthritis | 11 (35.4%) | 11 (19.6%) | 0.108 | 2.250 | 0.838~6.042 |
JSLE, juvenile-onset SLE; SLEDAI, SLE Disease Activity Index.